Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples